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Abstract
p21-activated kinases (Paks) are serine/threonine protein kinases involved in biological
events linked to malignant tumor progression. In this study, expression of Pak1, p-Pak2
Ser20, Pak4, pPak4 Ser474 in 21 normal endometrium, 16 hyperplastic endometrium
without atypia, 17 atypical complex hyperplasia and 67 endometrial cancers was assessed
by immunohistochemistry and correlated with clinicopathological parameters. We also
accessed the proliferative role and downstream targets of Pak1 in endometrial cancer. Pak1
was expressed in cytoplasm whereas Pak4 and p-Pak4 were expressed in both cytoplasm
and nucleus of endometrial tissues. In normal endometrium, significantly higher Pak1 (P =
0.028) and cytoplasmic p-Pak2 (P = 0.048) expression was detected in proliferative endome-
trium than secretory endometrium. Pak1, cytoplasmic and nuclear Pak4 and nuclear p-Pak4
was significantly overexpressed in endometrial cancer when compared to atrophic endome-
trium (all P<0.05). Moreover, type I endometrioid carcinomas showed significantly higher
Pak1 expression than type II non-endometrioid carcinomas (P<0.001). On the other hand,
Pak1, Pak4 and p-Pak4 expression negatively correlated with histological grade (all P<0.05)
while p-Pak2 and cytoplasmic Pak4 expression inversely correlated with myometrial invasion
(all P<0.05). Furthermore, patients with endometrial cancers with lower cytoplasmic Pak4
expression showed poorer survival (P = 0.026). Multivariate analysis showed cytoplasmic
Pak4 is an independent prognostic factor. Functionally, knockdown of Pak1, but not Pak4, in
endometrial cancer cell line led to reduced cell proliferation along with reduced cyclin D1,
estrogen receptor (ERα) and progestogen receptor (PR) expression. Significant correlation
between Pak1 and PR expression was also detected in clinical samples. Our findings sug-
gest that Pak1 and cytoplasmic p-Pak2may promote cell proliferation in normal endometrium
during menstral cycle. Pak1, cytoplasmic and nuclear Pak4 and nuclear p-Pak4 are involved
in the pathogenesis of endometrial cancer especially in postmenopausal women. Pak1 pro-
mote endometrial cancer cell proliferation, particular in type I endometrioid carcinoma. Cyto-
plasmic Pak4 can be potential prognostic marker in endometrial cancer.
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Introduction
Endometrial cancer is the most common gynecological malignancy worldwide [1] and its inci-
dence in Asia is rising. It can be classified into two major clinicopathological types. Estrogen
dependent type I endometrioid carcinoma, comprises about 80% of endometrial cancers, is
usually associated with endometrial hyperplasia [2, 3]. Type II non-endometroid carcinoma,
which is estrogen-independent and includes serous carcinoma and clear cell carcinoma, usually
occurs in atrophic endometrium [2, 3]. Type I endometrioid carcinoma has favorable progno-
sis while type II endometrial carcinoma is more aggressive [2, 3].
p21-activated serine/threonine kinases (Paks) are effectors for the small Rho GTPases Rac1
and Cdc42 that play important roles in a variety of cellular functions, including cell morpho-
genesis, motility, survival, anchorage-independent growth and angiogenesis, all of which are
prerequisite steps for tumor formation and tumor invasion [4, 5]. Based on different domain
structures and biochemical properties, the six members of Pak family are classified into Group
I (Paks1-3) and Group II (Paks 4–6), which have different expression pattern, substrate priority
and functional specificity in various tissues [5–7].
We have recently identified Pak1 and Pak4 as prognostic markers and potential therapeutic
targets for ovarian cancer [8, 9]. Increased phosphorylated (p)-Pak2Ser20 expression in ovarian
cancer was also detected [9]. Pak1 and Pak4 promote ovarian cancer cell migration and invasion
through the p38/VEGF pathway and the c-Src/MEK-1/MMP2 pathway, respectively [8, 9]. Pak4
also induce ovarian cancer cell proliferation through the Pak4/c-Src/EGFR/cyclin D1/CDC25A
pathway [8]. We also revealed overexpression of Pak1 in choriocarcinoma and hydatidiform
moles that progressed to aggressive disease [10]. Pak1 regulate choriocarcinoma cell prolifera-
tion, migration and invasion ability in association with altered level of p16, VEGF and
MT1-MMP [10].
Up-regulation of Pak1 and Pak4 has also been observed in other human cancers [4, 5, 11],
such as breast and colon cancers. A recent study has reported that Pak1 is down-regulated by
progesterone during the secretory phase in normal endometrium [12]. However, differential
expression of Paks in endometrial carcinoma is limited. Herein, the expression and localization
of Pak1, phosphorylated (p)-Pak2Ser20, Pak4 and p-PAK4Ser474 (the activated form) in normal,
hyperplastic and cancerous endometrium was assessed and correlated with clinicopathological
parameters. The proliferative role and downstream targets of Pak1 in endometrial cancer was
further investigated.
Materials and Methods
Clinical samples
Sixty-seven formalin fixed, paraffin embedded samples of endometrial cancers including
56 endometrioid carcinomas, 7 serous carcinomas and 4 clear cell carcinomas were retrieved
from Department of Pathology, the University of Hong Kong, Queen Mary Hospital for immu-
nohistochemistry. Clinical and pathological parameters including estrogen receptor alpha
(ERα) and progesterone receptor (PR) status [13] as assessed by immunohistochemistry was
retrieved. Twenty-one samples of normal endometrium (including 10 atrophic, 5 secretory and
6 proliferative endometrium), 16 samples of hyperplastic endometrium without atypia (includ-
ing 7 simple hyperplasia and 9 complex hyperplasia) and 17 samples of atypical complex
hyperplasia were also retrieved. Among the 17 atypical complex hyperplasia, 8 cases were pure
atypical hyperplasia while 9 cases subsequently developed endometrial cancers (atypical hyper-
plasia with endometrial cancers). The average age of these patients was 57.2 years (range 20–82
years). The mean follow-up period was 42.75 months (range 1–108 months). Written informed
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consent was obtained by all patients. This study was approved by the Institutional Ethical
Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster
(HKU/HA HKW IRB). Haematoxylin Eosin sections were examined by pathologists to review
the diagnosis and to ensure that each sample is composed of more than 75% tumor cells.
Cell lines
A human normal endometrial cell line (NEM), extended from primary culture of normal endo-
metrial cells from a ~ 40-year old premenopausal female with regular 28-day menstrual cycles,
was kindly given by Prof. Doris Benbrook (University of Oklahoma Health Sciences Center)
[14]. Three human endometrial cancer cell lines, HEC-1B, HEC-1A and RL95-2 were from
ATCC (Manassas, VA). All culture were cultured as previously described [15].
Transient knockdown of Pak1 and Pak4 in RL95-2
Cells were transfected with 100 nM each of siGENOME Smart-pool for Pak1, Pak4 and siCon-
trol nontargeting siRNA pool (Dharmacon, Lafayette, CO), using SilentFect (Bio-Rad Labora-
tories, Hercules, CA) per manufacturer’s instructions for 48 hours before RNA and protein
extraction, cell counting and cell plating [10].
Immunohistochemistry
Briefly, formalin-fixed paraffin-embedded sections were stained with antibodies against Pak1,
p-Pak2Ser20, Pak4 and p-Pak4 Ser474 (as listed in S1 Table) using EnVision+ Dual Link System
(K4061; Dako, Carpinteria, CA) [8–10]. Microwave antigen recovery was performed using cit-
rate buffer (pH 6.0). Omission or substitution of the primary antibody with preimmune IgG
serum was used as a negative control. Both the intensity and percentage of stained epithelial
cells were evaluated. Immunoreactivity was evaluated semiquantitatively by intensity and per-
centage of epithelium stained. Staining intensity was scored as 0 (negative), 1 (weak), 2 (mild),
3 (moderate) and 4 (strong). The percentage of positive cells was rated as 0 (<5%), 1 (5%-
25%), 2 (26%-50%), 3 (51%-75%) and 4 (>75%). A composite “Histoscore” was given by multi-
plying the staining intensity (0–4) by the percentage of stained cells (0–4) with a maximum
score of 16 [16].
Real-time PCR
Total RNA was extracted from cancer cell lines using Trizol reagent (Invitrogen). 2.5 μg total
RNA was reverse transcribed by SuperScript Reverse Transcriptase (Invitrogen, San Diego,
CA). Real-time PCR was performed with ABI Prism 7700 sequence detection system (Applied
Biosystems, Foster City, CA) [17, 18]. Primer sequences for Pak1, Pak4, CDC25A, cyclin D1,
ERα, PR (target both PRA and PRB isoforms) and GAPDH (as internal control) were shown in
S2 Table. The PCR purity was confirmed by gel electrophoresis.
Immunoblotting
Cells were harvested with lysis buffer (0.125 M Tris, pH 6.8 at 22 oC containing 1% NP-40
(v/v), 2 mM EDTA, 2 mMN-ethylmaleimide, 2 mM PMSF, 1 mM sodium orthovanadate and
0.1 μM sodium okadate], and cleared by centrifugation at 4°C. Protein concentration was
determined by DC (detergent compatible) protein assay (Bio-Rad Laboratories, Hercules, CA).
20 μg protein was resolved by SDS-PAGE, transferred to polyvinylidene difluoride membrane,
and hybridized with corresponding antibodies (as listed in S1 Table) [17, 18].
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Cell proliferation was determined by cell count method
3 x 104 cells were seeded in 6-well culture plates. Cell number was counted using trypan blue
dye exclusion with hematocytometer at day 4 [18].
Statistical Analysis
Statistical analysis was performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL).
Mann-Whitney test was applied for comparison between two groups. Kruskal-Wallis rank
test was applied for comparison among multiple groups. Survival analysis was performed by
Kaplan-Meier analysis and log-rank test. P values< 0.05 were considered as statistically
significant.
Result
Expression of Pak1 and cytoplasmic p-Pak2 Ser20 were higher in
proliferative endometrium. Pak1, cytoplasmic and nuclear Pak4 and
nuclear p-Pak4 Ser474 were overexpressed in endometrial cancer when
compared with atrophic endometrium
By immunohistochemistry, Pak1 was predominately expressed in the cytoplasm of endometrial
tissues with only focal nuclear staining detected (Fig 1A). In normal endometrial samples, atro-
phic and secretory endometrium showed weak expression whereas proliferative endometrium
displayed strong expression (Fig 1A i-iii). Hyperplastic endometrium and endometrial cancers
showed moderate to strong expression (Fig 1A iv-ix). Pak1 expression in proliferative endome-
trium was significantly higher than that in atrophic (P = 0.001) and secretory (P = 0.004)
endometrium, atypical hyperplasia (P = 0.042) and endometrial cancers (P = 0.044) (Fig 1B).
Significantly higher Pak1 expression in hyperplastic endometrium and endometrial cancers
than in atrophic endometrium (both P<0.05) was observed (Fig 1B). Although higher Pak1
expression was found in hyperplastic endometrium and endometrial cancers than secretory
endometrium, significant difference was only reached between simple/complex hyperplasia
and secretory endometrium (Fig 1B). Similar Pak1 expression was detected in hyperplastic
endometrium and endometrial cancers.
p-Pak2 was detected in both cytoplasm and nucleus of endometrial tissues (Fig 2A).
Among all categories, proliferative endometrium showed the strongest cytoplasmic and
nuclear p-Pak2 expression (Fig 2A). Atrophic and secretory endometrium as well as endome-
trial cancers showed weak cytoplasmic and nuclear p-Pak2 expression whereas hyperplastic
endometrium showed moderate cytoplasmic and nuclear p-Pak2 expression (Fig 2A). Cyto-
plasmic p-Pak2 expression in proliferative endometrium was significantly higher than that
in all other categories (all P<0.05) except complex hyperplasia whereas nuclear p-Pak2 only
showed significantly higher expression in proliferative endometrium than atrophic (P =
0.046) and secretory (P = 0.028) endometrium and endometrial cancers (P = 0.007) (Fig 2B).
Although higher cytoplasmic and nuclear p-Pak2 expression was found in hyperplastic endo-
metrium than atrophic endometrium, only complex hyperplasia (P = 0.007) and pure atypical
hyperplasia (P = 0.013) showed significant higher cytoplasmic p-Pak2 expression (Fig 2B). Fur-
thermore, there was significant reduced cytoplasmic and nuclear p-Pak2 expression in endo-
metrial cancers than that in complex hyperplasia (P = 0.009 and P = 0.006, respectively) and
pure atypical hyperplasia (P = 0.038 and P = 0.042, respectively) (Fig 2B).
Pak4 was expressed in both cytoplasm and nucleus of endometrial tissues (Fig 3). Cyto-
plasmic and nuclear Pak4 showed weak expression in atrophic endometrium and moderate
to strong expression in secretory, proliferative, hyperplastic endometrium and endometrial
p21-Activated Kinases in Endometrial Carcinoma
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cancers (Fig 3). Cytoplasmic Pak4 expression in atrophic endometrium was significantly
lower than that in other categories (all P<0.05) (Fig 3B, upper panel). Significantly higher cyto-
plasmic Pak4 expression was also found in secretory endometrium than complex hyperplasia
(P = 0.047) and endometrial cancers (P = 0.036) (Fig 3B, upper panel). Nuclear Pak4 in atro-
phic endometrium also displayed lower expression than other categories. However, significant
difference of nuclear Pak4 expression only observed between endometrial cancers and atrophic
endometrium (P = 0.026) (Fig 3B, lower panel). There is no significant difference of cyto-
plasmic and nuclear Pak4 expression between other categories.
p-Pak4 was also detected in both cytoplasm and nucleus of endometrial tissues (Fig 4A).
Cytoplasmic p-Pak4 showed weak to moderate expression in all categories (Fig 4A) and
Fig 1. (A) Pak1 immunoreactivity in normal atrophic endometrium (i), secretory endometrium (ii), proliferative endometrium (iii), simple
hyperplasia (iv), complex hyperplasia (v), pure atypical hyperplasia (vi), atypical hyperplasia (vii), endometrioid carcinomas (viii) and non-
endometrioid carcinomas (ix). (B) Bar chart showing the immunoreactivity of Pak1 in normal atrophic endometrium (Atrophic), secretory
endometrium (Secretory), proliferative endometrium (Proliferative), simple hyperplasia (SH), complex hyperplasia (CH), pure atypical hyperplasia
(Pure AH), atypical hyperplasia (AH) and endometrial cancers (EmCa). *, P<0.05; **, P<0.005; compared to normal atrophic endometrium by
Mann-Whitney test. (C) Bar chart showing the immunoreactivity of Pak1 in endometrioid carcinomas (ca) and non-endometrioid carcinomas. The
immunoreactivity of Pak1 was analyzed by Mann-Whitney test. (D) Kaplan-Meier survival curves for endometrial cancer patients with two different
expression levels of Pak1 (cut off at mean).
doi:10.1371/journal.pone.0133467.g001
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significant difference was only found between proliferative endometrium and simple hyper-
plasia (P = 0.041) (Fig 4B, upper panel). Weak to moderate nuclear p-Pak4 expression was
observed in atrophic endometrium whereas other categories displayed strong expression (Fig
4A). Significant difference was found between atrophic endometrium and other categories (all
P<0.05) (Fig 4B, lower panel). Since the present study involved 6 proliferative endometrium
cases only, the error bar for nuclear pPak2 and Pak4 in proliferative endometrium is relatively
large.
Up-regulation of Pak1 and Pak4 mRNA and protein expression was also found in cancer
cell lines (HEC-1B, HEC-1A and RL95-2) compared with normal endometrial cells by qPCR
(Fig 5A) andWestern blot analysis (Fig 5B), respectively.
Fig 2. (A) p-Pak2 immunoreactivity in normal atrophic endometrium (i), secretory endometrium (ii), proliferative endometrium (iii), simple
hyperplasia (iv), complex hyperplasia (v), pure atypical hyperplasia (vi), atypical hyperplasia (vii) and endometrial cancers (viii). (B) Bar chart
showing the immunoreactivity of cytoplasmic (upper panel) and nuclear (lower panel) p-Pak2 in normal atrophic endometrium (Atrophic),
secretory endometrium (Secretory), proliferative endometrium (Proliferative), simple hyperplasia (SH), complex hyperplasia (CH), pure atypical
hyperplasia (Pure AH), atypical hyperplasia (AH) and endometrial cancers (EmCa). *, P<0.05; **, P<0.005; compared to normal atrophic
endometrium by Mann-Whitney test. (C) Kaplan-Meier survival curves for endometrial cancer patients with two different expression levels of
cytoplasmic (upper panel) and nuclear (lower panel) p-Pak2 (cut off at mean).
doi:10.1371/journal.pone.0133467.g002
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Pak1, Pak4 and p-Pak4 expression correlated with clinicopathological
parameters. Pak1 expression correlated with PR
Pak1 expression was found to correlate significantly with histological type, histological grade
(grade 1/2 vs. 3) and patients’ age at diagnosis (all P<0.05), but not with other clinical parame-
ters (S3 Table). Patients with type I endometrioid carcinoma (Fig 1C), Grade 1 and 2 and
age 57 displayed higher Pak1 expression than those with type II serous and clear cell carci-
noma, grade 3 and age> 57. Significantly higher cytoplasmic and nuclear p-Pak2 as well as
cytoplasmic Pak4 expression was observed in superficial myometrial invasion than deep myo-
metrial invasion (all P<0.05) (S3 Table). There was a significant correlation existed between
Pak4 and p-Pak4 expression (both cytoplasmic and nuclear) and histological grade (all
Fig 3. (A) Pak4 immunoreactivity in normal atrophic endometrium (i), secretory endometrium (ii), proliferative endometrium (iii), simple
hyperplasia (iv), complex hyperplasia (v), pure atypical hyperplasia (vi), atypical hyperplasia (vii) and endometrial cancers (viii). (B) Bar chart
showing the immunoreactivity of cytoplasmic (upper panel) and nuclear (lower panel) Pak4 in normal atrophic endometrium (Atrophic), secretory
endometrium (Secretory), proliferative endometrium (Proliferative), simple hyperplasia (SH), complex hyperplasia (CH), pure atypical hyperplasia
(Pure AH), atypical hyperplasia (AH) and endometrial cancers (EmCa). *, P<0.05; **, P<0.005; compared to normal atrophic endometrium by
Mann-Whitney test. (C) Kaplan-Meier survival curves for endometrial cancer patients with two different expression levels of cytoplasmic (upper
panel) and nuclear (lower panel) Pak4 (cut off at mean).
doi:10.1371/journal.pone.0133467.g003
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P<0.05) (S3 Table). Higher grade of tumors showed lower expression of Pak4 and p-Pak4.
Cytoplasmic Pak4 showed significantly lower expression in patients with late stage disease and
cancers involving cervix (all P<0.05) (S3 Table). No significant correlation between expression
of p-Pak2, Pak4 and p-Pak4 with other clinical parameters was found.
Kaplan-Meier-survival analyses revealed that lower expression of cytoplasmic Pak4
(P = 0.026), but not Pak1, nuclear and cytoplasmic p-Pak2, nuclear Pak4, nuclear and cyto-
plasmic p-Pak4, resulted in a poorer survival in endometrial cancer patients (Figs 1D, 2C, 3C
and 4C). Multivariate analysis revealed that cytoplasmic Pak4 is an independent prognostic
factor (P = 0.037).
Fig 4. (A) p-Pak4 immunoreactivity in normal atrophic endometrium (i), secretory endometrium (ii), proliferative endometrium (iii), simple
hyperplasia (iv), complex hyperplasia (v), pure atypical hyperplasia (vi), atypical hyperplasia (vii) and endometrial cancers (viii). (B) Bar chart
showing the immunoreactivity of cytoplasmic (upper panel) and nuclear (lower panel) p-Pak4 in normal atrophic endometrium (Atrophic),
secretory endometrium (Secretory), proliferative endometrium (Proliferative), simple hyperplasia (SH), complex hyperplasia (CH), pure atypical
hyperplasia (Pure AH), atypical hyperplasia (AH) and endometrial cancers (EmCa). *, P<0.05; **, P<0.005; compared to normal atrophic
endometrium by Mann-Whitney test. (C) Kaplan-Meier survival curves for endometrial cancer patients with two different expression levels of
cytoplasmic (upper panel) and nuclear (lower panel) Pak4 (cut off at mean).
doi:10.1371/journal.pone.0133467.g004
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Knockdown of Pak1 in endometrial cancer cells reduced cell proliferation
and down-regulated cyclin D1, ERα and PR
To determine the proliferative role of Pak1 and Pak4 in endometrial cancer cells, transient
knockdown of Pak1 and Pak4 in RL95-2 was performed by siRNA approach. After confirming
the specific knockdown of Pak1 and Pak4 mRNA (Fig 6A) and protein (Fig 6B), the effect on
cell proliferation was determined by cell count method. Pak1 depleted RL95-2 showed signifi-
cantly reduced proliferation rate when compared with control cells that transfected with
control siRNA (Fig 6C). However, no significant difference in the proliferation rate after
knockdown of Pak4 in RL95-2 was found (Fig 6C). Moreover, knockdown of Pak1 in RL95-2
significantly down-regulated cell cycle-related gene cyclin D1 and steroid receptors, ERα and
PR, but have no effect on another cell cycle-related gene CDC25A, as evaluated by qPCR
(Fig 6D). Cyclin D1 was also significantly reduced in siPak4 RL95-2 (Fig 6D).
Discussion
Our data showed significantly higher Pak1 and cytoplasmic p-Pak2 expression in normal pro-
liferative endometrium than secretory endometrium, suggesting Pak1 and p-Pak2 may be asso-
ciated with estrogen regulated proliferative activity of endometrium during menstral cycle. In
breast cancer, regulation of Pak1 by estrogen has been reported [19]. The findings also concur
with previous report down-regulation of Pak1 by progesterone in normal secretory endome-
trium [12].
The proliferative role of Pak1 and Pak2 has been documented in normal cells. For example,
in fibroblasts, Pak1 phosphorylated by CDC2A has been found to alter post-mitotic spreading,
which is an essential step for cell cycle progression and proliferation [20]. Our previous study
also revealed the involvement of Pak1 in trophoblast proliferation [10]. In normal mammary
epithelial cells, hyperactive Rac3 was found to enhance cell proliferation through Pak2 [21].
Phosphorylation of Pak2 at Ser20, its corresponding phosphorylation site of Pak1 at Ser20 has
been found to modulate Nck binding between cytosol and membrane, thus regulate cell migra-
tion [22, 23]. In our previous study, cytoplasmic p-Pak2 was detected in cytotrophoblast
which can be considered as trophoblastic stem cells responsible for proliferation [10]. We also
detected nuclear p-Pak2 in endometrial tissues, albeit the roles of p-Pak2 in nucleus still need
to be further studied. Like Pak1 and Pak4 [8, 24], p-Pak2 in nucleus may play function on gene
transcription. In future study, it is interest to determine if estrogen can regulate Pak1 and p-
Pak2 expression leading to increased proliferative activity of endometrium during menstral
cycle.
Fig 5. mRNA (A) and protein (B) expression of Pak1 and Pak4 in a human normal endometrial cell line, and three endometrial cancer cell lines,
HEC-1B, HEC-1A and RL95-2, as determined by qPCR and immunoblot analysis respectively.
doi:10.1371/journal.pone.0133467.g005
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We found significantly higher Pak1, cytoplasmic and nuclear Pak4 and nuclear p-Pak4
expression in endometrial cancers than atrophic endometrium. Increased expression of Pak1
and Pak4 was also detected in endometrial cancer cell lines. Most functions of Pak4 are depen-
dent on its kinase activity [8]. In our previous study, besides cell migration executed in the
cytoplasm, we have revealed regulation of gene transcription by nuclear Pak4 in ovarian cancer
[8]. The present findings suggest that Pak1, cytoplasmic and nuclear Pak4 and nuclear p-Pak4
may play important roles in the pathogenesis of endometrial cancer especially in postmeno-
pausal women and can be useful in the detection of endometrial carcinoma in small endome-
trial biopsy from postmenopausal women.
We also demonstrated decreased proliferation in endometrial cancer cells after Pak1 knock-
down along with reduced cyclin D1 expression. We and others have documented proliferative
role of Pak1 in other human cancers, such as breast cancer [25], squamous nonsmall cell lung
carcinoma [26] and choriocarcinoma [10]. Overexpression of cyclin D1, a D-type cyclin regu-
lating G1-S phase cell cycle progression, has been reported in endometrial cancer [27, 28].
Previous study also found that Pak1 regulates prolactin mediated cyclin D1 promoter activity
in breast cancer [29]. The present findings suggest that Pak1 may regulate cell proliferation
through the alteration of cell cycle progression. Since cyclin D1 can be an alternative target of
therapy [30] and small-molecule inhibitors for the Pak family are being developed [7, 31], com-
bined-targeted therapy may be achieved for targeting endometrial cancer. Although we have
revealed proliferation enhancing effect of Pak4 on ovarian cancer [8] and detected reduced
cyclin D1 expression in RL95-2 cells after Pak4 knockdown in the present study, no significant
effect of Pak4 on endometrial cancer cell proliferation could be demonstrated when Pak4 was
transiently silenced in RL95-2 cells in the present study. It is possible that effect on cell prolifer-
ation needs to be determined using stable knockdown cells with longer incubation time before
doing cell count method. Such possibility should be considered in future study. The roles of
Pak4 in endometrial cancer need to be further elucidated.
Fig 6. Transient knockdown of Pak1 (siPak1) and Pak4 (siPak4) mRNA and protein expression by qPCR (A) andWestern blot analysis (B)
respectively in RL95-2. (C) Cell proliferation rate of RL95-2 in control, siPak1 and siPak4 after 4 days was displayed as fold change compared to
control; n = 3; **, P<0.005. (D) qPCR analysis on the mRNA expression of CDC25A, cyclin D1, ERα and PR in control, siPak1 and siPak4 RL95-2.
Bars, means±SD of three experiments; **, P<0.005, Mann-Whitney test.
doi:10.1371/journal.pone.0133467.g006
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We demonstrated significantly higher Pak1 expression in Type I endometrioid carcinoma
than Type II non-endometrioid carcinoma. Type I endometrioid carcinoma is an estrogen-
dependent tumor [2, 3]. Although previous study has shown no effect on Pak1 expression after
estrogen treatment in Ishikawa cells (a well-differentiated endometrial adenocarcinoma cell
line) [12], we found ERα and ER target gene PR, was reduced after knockdown of Pak1 in
RL95-2. Moreover, the positive correlation between Pak1 and PR expression in our endome-
trial cancer clinical samples further support their link. The strong association between ERα
and PR expression and Type I endometrioid carcinoma as compared with Type II non-endo-
metrioid carcinoma [32], explains the effectiveness of progestin therapy for Type I endome-
trioid carcinoma. In breast cancer cells, Pak1 inhibitor blocked ER transactivation functions
and downregulated ER target product PR (both PRA and PRB isoforms) protein expression
[33]. Moreover, Pak1 mediated phosphorylation of ERα at Ser305 has shown to enhance trans-
activation of ERα leading to up-regulation of ER-regulated genes, such as cyclin D1, which in
turn promote hormone-independent growth of breast cancer cells [33–35]. It is possible that
Pak1 is one of upstream mediators for ERα and PR expression in Type I endometrioid carci-
noma and Pak1 may enhance growth of endometrial cancer cells through regulating ERα
We found lower expression of cytoplasmic Pak4 was associated with poorer prognosis in
endometrial cancers. Earlier studies including ours have found higher Pak4 expression contrib-
uting to poor prognosis in patients of ovarian cancer [8] and oral squamous-cell carcinoma
[36]. This relatively surprising association may be related to the unique biological environment
of the endometrium, being a cyclical proliferative tissue sensitive to hormone regulation. The
reason for such observation needs to be further studied in future.
In summary, Pak1 and cytoplasmic p-Pak2 may play roles in the proliferative activity of
endometrium during menstral cycle. Pak1, cytoplasmic and nuclear Pak4 and nuclear p-Pak4
are involved in the pathogenesis of endometrial cancer and can be potential therapeutic targets
especially in postmenopausal women. Pak1 enhance endometrial cancer cell proliferation par-
ticular in type I endometrioid carcinoma. Cytoplasmic Pak4 can be potential prognostic
marker in endometrial cancer.
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